* Dose escalation is complete and a GMI-1271 dose was
identified for phase 2 testing
The post BRIEF-Glycomimetics’ GMI-1271 yields high remission rates in phase 1 portion of phase 1/2 clinical trial for AML appeared first on NASDAQ.
BRIEF-Glycomimetics’ GMI-1271 yields high remission rates in phase 1 portion of phase 1/2 clinical trial for AML
